Roche has dosed the first patient in a Phase I pharmacokinetic trial with a subcutaneous formulation using Halozyme Therapeutics’ Enhanze Technology of a biologic directed to a Roche exclusive target. This has triggered a milestone payment under the collaboration agreement between the two companies. Roche has also selected an additional exclusive target under the existing license and collaboration agreement. Roche will pay Halozyme for exclusive, global rights for the application of its...